Shin Nippon Biomedical
As of the edition of 20 October 2026, Shin Nippon Biomedical runs 1 drug, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- Satsuma Pharmaceuticals, Inc.: acquired in 2023; successor Shin Nippon Biomedical Laboratories, Ltd.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Dihydroergotamine | none listed | 1 |
A route B row is one company at one target.